Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy.

"Declarations Conflict of interestRS has received honoraria from Bristol-Myers Squibb, Lilly, Roche, Taiho, Astra Zeneca, DKSH and MSD; has advisory activity with Bristol-Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD and AstraZeneca; received research funding from MSD and Paxman Coolers; and has received travel grants from AstraZeneca, Eisai, Roche and Taiho Pharmaceutical. WPY has advisory activity with Abbvie, Amgen, AstraZeneca, BMS, Ipsen, Novartis, MSD; is a speaker with Bayer, Eisai, Lilly, Sanofi, Taiho. The rest of the authors have no conflicts of interest to declare. Conflict of interest RS has received honoraria from Bristol-Myers Squibb, Lilly, Roche, Taiho, Astra Zeneca, DKSH and MSD; has advisory activity with Bristol-Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD and AstraZeneca; received research funding from MSD and Paxman Coolers; and has received travel grants from AstraZeneca, Eisai, Roche and Taiho Pharmaceutical. WPY has advisory activity with Abbvie, Amgen, AstraZeneca, BMS, Ipsen, Novartis, MSD; is a speaker with Bayer, Eisai, Lilly, Sanofi, Taiho. The rest of the authors have no conflicts of interest to declare."

"Funding RS is supported by the National Medical Research Council (NMRC) (NMRC/Fellowship/0059/2018 and NMRC/MOH/000627). All other authors have no funding to declare. As part of the Singapore Gastric Cancer Consortium, the study is also partially funded by the National Medical Research Council Open Fund-Large Collaborative Grant (OFLCG18May-0023)."